Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults

详细信息    查看全文

• 作者：James F. Cummings^a ; ^{james.f.cummings6.mil@mail.mil" class="auth_mail} ; ^{Jamesfcummings@gmail.com" class="auth_mail} ; Melanie L. Guerrero^a ; James E. Moon^a ; Paige Waterman^a ; Robin K. Nielsen^a ; Stacie Jefferson^b ; F. Liaini Gross^b ; Kathy Hancock^b ; Jacqueline M. Katz^b ; Vidadi Yusibov^c ; Fraunhofer USA Center for Molecular Biotechnology Study Group 1
• 关键词：Influenza A ; H1N1 ; Recombinant vaccine ; Hemagglutinin ; Plant-produced
• 刊名：Vaccine
• 出版年：17 April, 2014
• 年：2014
• 卷：32
• 期：19
• 页码：2251-2259
• 全文大小：858 K

文摘

Background

Novel influenza viruses continue to pose a potential pandemic threat worldwide. In recent years, plants have been used to produce recombinant proteins, including subunit vaccines. A subunit influenza vaccine, HAC1, based on recombinant hemagglutinin from the 2009 pandemic A/California/04/2009 (H1N1) strain of influenza virus, has been manufactured using a plant virus-based transient expression technology in Nicotiana benthamiana plants and demonstrated to be immunogenic and safe in pre-clinical studies (Shoji et al., 2011).

Methods

A first-in-human, Phase 1, single-center, randomized, placebo-controlled, single-blind, dose escalation study was conducted to investigate safety, reactogenicity and immunogenicity of an HAC1 formulation at three escalating dose levels (15 渭g, 45 渭g and 90 渭g) with and without Alhydrogel^庐, in healthy adults 18-50 years of age (inclusive). Eighty participants were randomized into six study vaccine groups, a saline placebo group and an approved monovalent H1N1 vaccine group. Recipients received two doses of vaccine or placebo (except for the monovalent H1N1 vaccine cohort, which received a single dose of vaccine, later followed by a dose of placebo).

Results

The experimental vaccine was safe and well tolerated, and comparable to placebo and the approved monovalent H1N1 vaccine. Pain and tenderness at the injection site were the only local solicited reactions reported following vaccinations. Nearly all adverse events were mild to moderate in severity. The HAC1 vaccine was also immunogenic, with the highest seroconversion rates, based on serum hemagglutination-inhibition and virus microneutralization antibody titers, in the 90 渭g non-adjuvanted HAC1 vaccine group after the second vaccine dose (78% and 100%, respectively).

Conclusions

This is the first study demonstrating the safety and immunogenicity of a plant-produced subunit H1N1 influenza vaccine in healthy adults. The results support further clinical investigation of the HAC1 vaccine as well as demonstrate the feasibility of the plant-based technology for vaccine antigen production.